BACKGROUND Tuberculosis, caused by Mycobacterium tuberculosis (MTB), is the most notified disease in the world. Development of resistance to first line drugs by MTB is a public health concern. As a result, there is the search for new and novel sources of antimycobacterial drugs for example from medicinal plants. In this study we determined the in vitro antimycobacterial activity of n-Hexane sub...

The objective of this study was to investigate the relationship between the antimycobacterial properties of the antileprosy drug clofazimine and its stimulatory effect on the release of reactive oxidants by polymorphonuclear leukocytes by using a variety of phenazine derivatives. The effects of these compounds on myeloperoxidase-mediated iodination, luminol-enhanced chemiluminescence, and the r...

results results of the current study showed that the minimum inhibitory concentration value of cinnamaldehyde against m. tuberculosis was 200 µg/ml. moreover, rt-pcr data showed that a total of 25 genes were regulated by the cinnamaldehyde. of these, 12 genes were up-regulated, and 13 genes were down-regulated. conclusions cinnamaldehyde is a pattern to expand the new anti-tb drugs, because the...

Abstract Nontuberculous mycobacteria can cause disseminated infections in immunocompromised patients and are challenging to treat because of antimicrobial resistance adverse effects prolonged multidrug treatment. We report successful treatment with bedaquiline, a novel antimycobacterial drug, as part combination therapy for 2 nontuberculous co-infected HIV.

Riminophenazines were specifically developed as drugs active against Mycobacterium tuberculosis but extensive research over several decades has shown that these compounds are also active against many other mycobacterial infections, particularly those caused by Mycobacterium leprae and the Mycobacterium avium complex (MAC). Clofazimine, the lead compound in this series, is included in the regime...